Li 2007

1 Treatments

Studied treatment  nateglinide 90 mg three times daily

Control treatment  repaglinide 1.0 mg three times daily

Concomittant treatments  -

2 Patients

Patients  Chinese patients with type 2 diabetes

Inclusion criteria  -

Exclusion criteria  -

3 Methods

Blinding  -

Design  Parallel groups

Centers  -

Geographical area  -

Sizes  115/115

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
</table>

5 References